Paclitaxel-loaded poly(lactide-co-glycolide)/poly(ethylene vinyl acetate) composite for stent coating by ultrasonic atomizing spray

Yuk, Soon Hong; Oh, Keun Sang; Park, Jinah; Kim, Soon-Joong; Kim, Jung Ho; Kwon, Il Keun

doi:10.1088/1468-6996/13/2/025005

Cited by 8 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In order to evaluate the release profiles of paclitaxel-loaded PEVA compared to a blend of PEVA and PLGA (85:10), BMSs were spray coated and immersed in PBS (pH 7.4) with 0.05 wt.% Tween 80 at physiologic temperature and 120 rpm rotation [64]. The research showed that the PEVA control had 35% paclitaxel release in 5 days but only 40% total release by day 30.…”

Section: Stent Coating Techniquesmentioning

confidence: 99%

Coating Techniques and Release Kinetics of Drug-Eluting Stents

Livingston

Tan

2015

Journal of Medical Devices

View full text Add to dashboard Cite

Implantation of drug-eluting stents (DESs) via percutaneous coronary intervention is the most popular treatment option to restore blood flow to occluded vasculature. The many devices currently used in clinic and under examination in research laboratories are manufactured using a variety of coating techniques to create the incorporated drug release platforms. These coating techniques offer various benefits including ease of use, expense of equipment, and design variability. This review paper discusses recent novel DES designs utilizing individual or a combination of these coating techniques and their resulting drug release profiles.

show abstract

Section: Stent Coating Techniquesmentioning

confidence: 99%

Coating Techniques and Release Kinetics of Drug-Eluting Stents

Livingston

Tan

2015

Journal of Medical Devices

View full text Add to dashboard Cite

show abstract

“…Several preclinical [33][34][35][36][37][38][39][40] and clinical studies [41][42][43] have used polyurethanes, silicones and PEVA as carriers for drug delivery in gastrointestinal malignancies. However, limited studies about localised drug delivery, particularly using these materials to oesophageal cancer have been conducted so far.…”

Section: Introductionmentioning

confidence: 99%

Influence of Polymer Composition on the Controlled Release of Docetaxel: A Comparison of Non-Degradable Polymer Films for Oesophageal Drug-Eluting Stents

et al. 2020

View full text Add to dashboard Cite

Following the huge clinical success of drug-eluting vascular stents, there is a significant interest in the development of drug-eluting stents for other applications, such as the treatment of gastrointestinal (GI) cancers. Central to this process is understanding how particular drugs are released from stent coatings, which to a large extent is controlled by drug-polymer interactions. Therefore, in this study we investigated the release of docetaxel (DTX) from a selection of non-degradable polymer films. DTX-polymer films were prepared at various loadings (1, 5 and 10% w/w) using three commercially available polymers including poly(dimethylsiloxane) (PSi), poly (ethylene-co-vinyl acetate) (PEVA) and Chronosil polyurethane (PU). The formulations were characterised using different techniques such as photoacoustic Fourier-transform infrared (PA-FTIR) spectrophotometry, X-ray diffraction (XRD) and differential scanning calorimetry (DSC). The effect of DTX on the mechanical properties of the films, in-vitro release, and degradation tests were also assessed. For all polymers and DTX loadings, the drug was found to disperse homogenously without crystallisation within the polymer matrix. While no specific interactions were observed between DTX and PSi or PEVA, hydrogen-bonding appeared to be present between DTX and PU, which resulted in a concentration-dependent decrease in the Young’s moduli of the films due to disruption of inter-polymeric molecular interactions. In addition, the DTX-PU interactions were found to modulate drug release, providing near-linear release over 30 days, which was accompanied by a significant reduction in degradation products. The results indicate that DTX-loaded PU films are excellent candidates for drug-eluting stents for the treatment of oesophageal cancer.

show abstract

“…The implantation of a stent coated with antithrombogenic agents into the infected lesion has been explored to regulate platelet aggregation . However, stent implantation in the long run stimulates smooth muscle cell migration and the rupture of the atheroma thin layer, causing thrombosis and restenosis (i.e., renarrowing of blood vessels). , Even though numerous advanced strategies, such as antithrombogenic agents or immunosuppressive drugs including sirolimus onto the surface of the stent via the spray-drying method and electrophoretic deposition (EPD) techniques, have been attempted for drug-eluting stent (DES) and some of them are effective, there still remains an inherent need for advanced means against in-stent restenosis and thrombosis. − …”

Section: Introductionmentioning

confidence: 99%

Advanced Cardiovascular Stent Coated with Nanofiber

Lee

2013

Mol. Pharmaceutics

View full text Add to dashboard Cite

Nanofiber was explored as a stent surface coating substance for the treatment of coronary artery diseases (CAD). Nanofibers loaded with nanoparticles containing β-estradiol were developed and exploited to prevent stent-induced restenosis through regulation of the reactive oxygen species (ROS). Eudragit S-100 (ES), a versatile polymer, was used as a nanoparticle (NP) base, and the mixtures of hexafluoro-2-propanol (HFIP), PLGA and PLA at varying ratios were used as a nanofiber base. β-Estradiol was used as a primary compound to alleviate the ROS activity at the subcellular level. Nile-Red was used as a visual marker. Stent was coated with nanofibers produced by electrospinning technique comprising the two-step process. Eudragit nanoparticles (ES-NP) as well as 4 modified types of NP-W (ES-NP were dispersed in H2O, which was mixed with HFIP (1:1 (v/v) and then subsequently added with 15% PLGA), NP-HW (ES-NP were dispersed in H2O, which was mixed with HFIP (1:1 (v/v)) already containing 15% PLGA), NP-CHA (ES-NP with a chitosan layer were added in H2O, which was mixed with HFIP (1:1 (v/v)) containing 15% PLGA), and NP-CHB (ES-NP with a chitosan layer were added in H2O, which was mixed with HFIP (1:1 (v/v)) containing the mixture of PLGA and PLA at a ratio of 4:1) were developed, and their properties, such as the loading capacity of β-estradiol, the release profiles of β-estradiol, cell cytotoxicity and antioxidant responses to ROS, were characterized and compared. Among composite nanofibers loaded with nanoparticles, NP-CHB had the maximal yield and drug-loading amount of 66.5 ± 3.7% and 147.9 ± 10.1 μg, respectively. The nanofibers of NP-CHB coated on metallic mandrel offered the most sustained release profile of β-estradiol. In the confocal microscopy study, NP-W exhibited a low fluorescent intensity of Nile-Red as compared with NP-HW, indicating that the stability of nanoparticles decreased, as the percentage volume of the organic solvent increased. Nanofibers incorporated with β-estradiol yielded a high endothelial proliferation rate, which was about 3-fold greater than the control (without β-estradiol). The cells treated with the enhanced level of H2O2 (>1 mM: as ROS source) were mostly nonviable (81.1 ± 12.4%, p < 0.01), indicating that ROS induce cell apoptosis and trigger the rupture of atheroma thin layer in a concentration dependent manner. Nanofibers containing β-estradiol (0.5 mM) lowered cellular cytotoxicity from 25.2 ± 4.9% to 8.1 ± 1.4% in the presence of 600 μM H2O2, and from 86.8 ± 8.4% to 59.4 ± 8.7% in the presence of 1.0 mM H2O2, suggesting that β-estradiol efficiently protected hPCECs from ROS induced cytotoxicity. The level of NO production in hPCECs in the presence of β-estradiol after 6 days of incubation was much greater than that of the control without β-estradiol. In summary, nanofibers loaded with nanoparticles containing β-estradiol could be used as a suitable platform for the surface coating of a cardiovascular stent, achieving enhanced endothelialization at the implanted sites of blood...

show abstract

Paclitaxel-loaded poly(lactide-co-glycolide)/poly(ethylene vinyl acetate) composite for stent coating by ultrasonic atomizing spray

Cited by 8 publications

References 19 publications

Coating Techniques and Release Kinetics of Drug-Eluting Stents

Coating Techniques and Release Kinetics of Drug-Eluting Stents

Influence of Polymer Composition on the Controlled Release of Docetaxel: A Comparison of Non-Degradable Polymer Films for Oesophageal Drug-Eluting Stents

Advanced Cardiovascular Stent Coated with Nanofiber

Contact Info

Product

Resources

About